Skip to content

Esperion target upped to $57 by UBS

June 28, 2017

UBS raised its price target on Esperion Therapeutics (NASDAQ: ESPR) to $57.00 (from $52.00) while maintaining a Buy rating, as the company announced FDA confirmation of the regulatory pathway to approval for the combination of 180 mg of bempedoic acid plus 10 mg ezetimibe.

Analyst Martin Auster highlights plan to commence a global pivotal Phase 3 bridging study during the fourth quarter of 2017 for the combination pill, with top-line results expected in 2018. According to the analyst, the fixed dose combination improves the bempedoic acid franchise.


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: